Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the studies of left ventricular dysfunction (SOLVD) trials

Circulation

Volumn 107, Issue 23, 2003, Pages 2926-2931

  Vermes, Emmanuelle ^a   Tardif, Jean Claude ^a   Bourassa, Martial G ^a   Racine, Normand ^a   Levesque, Sylvie ^a   White, Michel ^a   Guerra, Peter G ^a   Ducharme, Anique ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angiotensin; Fibrillation; Heart failure; Inhibitors

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO;

ADULT; AORTA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; FIBROSIS; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CANADA; COMORBIDITY; DISEASE-FREE SURVIVAL; ELECTROCARDIOGRAPHY; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038649984     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000072793.81076.D4     Document Type: Article

References (29)

1. Carson PE, Johnson GR. Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation. 1993;87(suppl VI):VI-102-VI-110.
2. Middlekauff HR, Stevenson WG. Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation. 1991;84:40-48.
3. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998;32:197-204.
4. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-703.
5. Bourassa MG, Gurné O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14A-19A.
6. Mathew J, Hunsberger S, Fleg J, et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest. 2000;118:914-922.
7. Li D, Fareh S, Leung TK. et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95.
8. Shi Y, Ducharme A, Li D. et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res. 2001;52:217-225.
9. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614.
10. Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54:456-461.
11. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
12. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
13. SOLVD Investigators. Studies of Left Ventricular Dysfunction (SOLVD): rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
14. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2001;38:1231-1266.
15. Pedersen OD, Bagger H, Køber L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-380.
16. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infaretion: the protective effects of captopril. Circulation. 1994;89:68-75.
17. Zou Y, Komuro I, Yamazaki T, et al. Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gβγ subunit, Src family, and Ras in cardiac fibroblasts. Circ Res. 1998;82:337-345.
18. mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319-8323.
19. Brilla CG, Zhou G. Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
20. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35:1669-1677.
21. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 2000;101:2678-2681.
22. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-2617.
23. Kaprielian R, Dupont E, Hafizi S, et al. Angiotensin II receptor type 1 mRNA is upregulated in atria of patients with end-stage heart failure. J Mol Cell Cardiol. 1997;29:2299-2304.
24. Solti F, Vecsey T, Kékesi V, et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989;23:882-886.
25. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 1997;96:1686-1695.
26. Webster MW, Fitzpatrick MA, Nicholls MG, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol. 1985;56:566-569.
27. Madrid AH, Bueno MG, Rebollo MG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation. 2002;106:331-336.
28. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe. Stroke. 2001;32:392-398.
29. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699-702.